{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T19:04:08Z","timestamp":1771009448912,"version":"3.50.1"},"reference-count":75,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,3,28]],"date-time":"2012-03-28T00:00:00Z","timestamp":1332892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1002\/ajh.23169","type":"journal-article","created":{"date-parts":[[2012,2,24]],"date-time":"2012-02-24T12:41:50Z","timestamp":1330087310000},"page":"562-568","source":"Crossref","is-referenced-by-count":15,"title":["Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post\u2010ASH symposium"],"prefix":"10.1002","volume":"87","author":[{"given":"Omar","family":"Abdel\u2010Wahab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier A.","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Finazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Crispino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Gisslinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Kralovics","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olatoyosi","family":"Odenike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kapil","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Barosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Jacques","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Noel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juergen","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Van Etten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tariq","family":"Mughal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,3,28]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-194548"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270108"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.163"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810069"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.47"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.82"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.77"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.621"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2011.31"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-367243"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22257"},{"key":"e_1_2_7_14_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.278.278","article-title":"Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT\u2010I (Abstract 278)","volume":"118","author":"Verstovsek S","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_15_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.279.279","article-title":"Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT\u2010II study (Abstract 279)","volume":"118","author":"Harrison C","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_16_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.3838.3838","article-title":"SAR302503: Interim safety, efficacy and long\u2010term impact on JAK2 V617F allele burden in a phase I\/II study in patients with myelofibrosis (Abstract 3838)","volume":"118","author":"Pardanani A","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_17_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.3849.3849","article-title":"An expanded multicenter phase I\/II study of CYT387, a JAK\u20101\/2 inhibitor for the treatment of myelofibrosis (Abstract 3849)","volume":"118","author":"Pardanani A","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_18_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.282.282","article-title":"Results of a phase 2 study of Pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, postpolycythemia vera, and postessential thrombocythemia myelofibrosis (Abstract 282)","volume":"118","author":"Komrokji R","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_19_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.794.794","article-title":"Prolonged low dose therapy with a pan\u2010deacetylase inhibtor, panobinostat (LBH589), in patients with myelofibrosis (Abstract 794)","volume":"118","author":"Mascarenhas J","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_20_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.1748.1748","article-title":"A phase II study of the HDAC inhibitor givinostat in combination with hydroxyurea in patients with polycythemia vera resistant to hydroxyurea monotherapy (Abstract 1748)","volume":"118","author":"Rambaldi A","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_21_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.280.280","article-title":"Complete hematological, molecular and histological remissions without cytoreductive treatment lasting after pegylated\u2010interferon \u03b1\u20102a (peg\u2010IFN\u03b1\u20102a) therapy in polycythemia vera (PV): Long term results of a phase 2 trial (Abstract 280)","volume":"118","author":"Turlure P","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_22_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.1759.1759","article-title":"Pomalidomide therapy for myelofibrosis: Analysis of results from three consecutive clinical trials (Abstract 1759)","volume":"118","author":"Begna K","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_23_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.1757.1757","article-title":"Phase II study of low\u2010dose pomalidomide in patients with myelofibrosis and significant anemia (hemoglobin <10 g\/dL) (Abstract 1757)","volume":"118","author":"Shastri A","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_24_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.1750.1750","article-title":"Results of phase II clinical trial MPD\u2010RC 101: Allogeneic hematopoietic stem cell transplantation conditioned with fludarabine\/melphalan in patients with myelofibrosis (Abstract 1750)","volume":"118","author":"Rondelli D","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-210039"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1112317108"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-325241"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.06.001"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.06.003"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-324707"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09586"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10102"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.2036011"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3123"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M106953200"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja0634829"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1210944"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.11.015"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3783"},{"key":"e_1_2_7_40_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.614.614","article-title":"Evaluating clonal dominance in a murine knock\u2010in model of Jak2V617F MPN (Abstract)","volume":"118","author":"Mullally A","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20060750"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.1009"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.58"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.621"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-363424"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni876"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1623"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.036350"},{"key":"e_1_2_7_49_2","first-page":"3971","article-title":"STAT5 activation is required for interleukin\u20109\u2010dependent growth and transformation of lymphoid cells","volume":"60","author":"Demoulin JB","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_7_50_2","article-title":"Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms","author":"Deshpande A","year":"2011","journal-title":"Leukemia"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1541"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.12.3249"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.021"},{"key":"e_1_2_7_54_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.2810.2810","article-title":"Characterization of Splenic CD34+ cells from patients with primary myelofibrosis (Abstract 2810)","volume":"118","author":"Wang X","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-218842"},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.9490"},{"key":"e_1_2_7_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21972"},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.05.015"},{"key":"e_1_2_7_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.269"},{"key":"e_1_2_7_61_2","article-title":"Critical requirement for Stat5 in a mouse model of polycythemia vera","author":"Yan D","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_62_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-397554"},{"key":"e_1_2_7_63_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-107748"},{"key":"e_1_2_7_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.10.013"},{"key":"e_1_2_7_65_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837"},{"key":"e_1_2_7_66_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"e_1_2_7_67_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-371096"},{"key":"e_1_2_7_68_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.277.277","article-title":"Survival and prognosis among 1,263 patients with polycythemia vera: An international study (Abstract 277)","volume":"118","author":"Tefferi A","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_69_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8021"},{"key":"e_1_2_7_70_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1109555"},{"key":"e_1_2_7_71_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.793.793","article-title":"Comparison of outcomes of advanced myelofibrosis patients treated with Ruxolitinib (INCB018424) to those of a historical control group: Survival advantage of Ruxolitinib therapy (Abstract 793)","volume":"118","author":"Verstovsek S","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_72_2","first-page":"118","article-title":"The MD Anderson cancer center (MDACC) experience with Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis: Long\u2010term Follow\u2010up outcomes of 107 patients from a phase I\/II study (Abstract 3851)","author":"Verstovsek S","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_73_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.120"},{"key":"e_1_2_7_74_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.281.281","article-title":"Dynamics of mutant alleles in patients with advanced essential thrombocythemia (ET) or polycythemia (PV) during pegylated interferon\u2010Alfa\u20102A (PEG\u2010IFN\u2010\u03b1\u20102A; Pegasys) therapy (Abstract 281)","volume":"118","author":"Quintas\u2010Cardama A","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_75_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22233"},{"key":"e_1_2_7_76_2","article-title":"A phase II trial of panobinostat, an orally available deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF), postessential thrombocythemia (ET), and postpolycythemia vera (PV) myelofibrosis (Abstract 630)","volume":"116","author":"DeAngelo DJTA","year":"2010","journal-title":"Blood"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23169","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T13:36:31Z","timestamp":1700573791000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,28]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1002\/ajh.23169"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23169","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,28]]}}}